Bristol-Myers Squibb (BMY) Stock: Buy, Sell, or Hold?
$62.91
+0.11 (+0.18%)
▲
5d:
-1.99%
30d:
+11.01%
90d:
-2.69%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Oct 29, 2026
0d
Protect BMY Gains
Updated Nov 11, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (46%)
Quality Score
48/100
Position
EXTENDED
30-Day Fair Range
$59.15 – $62.74
Position: EXTENDED
Forward P/E & Valuation
9.4x
FAIR
vs 9.5x historical avg
Wall Street Target
$65.25
+3.7% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$60.00 / $65.54
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: BMY shows conflicting indicators. Wait for confirmation before entering.
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Oct 30, 2026 at $62.74 · last confirmed Nov 10, 2026
Strength: 5.4/10
Get Alerted When BMY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$77.43
Based on 4.0% avg growth
INTRINSIC VALUE TODAY
$48.08
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BMY is currently trading at $62.91, which is considered extended relative to its 30-day fair value range of $59.15 to $62.74. The stock's valuation (Forward PE: 9.4) is in line with its historical norms (9.5). Remarkably, the market is currently pricing in an annual earnings decline of 0.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BMY is in a downtrend. Immediate support is located at $60.00, while resistance sits at $65.54.
Market Sentiment: The stock scores a mixed 46/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BMY is in a downtrend. Immediate support is located at $60.00, while resistance sits at $65.54.
Market Sentiment: The stock scores a mixed 46/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$59.15 -
$62.74
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
46.2%
Trading Range & Key Levels
30-Day Trading Range
$59.15 -
$62.74
Current vs Trading Range
EXTENDED
Support Level
$60.00
Resistance Level
$65.54
Current Trend
Downtrend
Technical data as of
Nov 11, 2026
Protect Your Profits
Holding BMY? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (46/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($65.25)
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
9.39
Wall Street Target
$65.25
(+3.7%)
Revenue Growth (YoY)
6.9%
Earnings Growth (YoY)
-2.8%
Profit Margin
18.5%
Valuation Discount vs History
-0.2% cheaper
PE vs Historical
9.4 vs 9.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.2%
(market-implied from PE analysis)
1-Year Target
$62.78
(0%)
2-Year Target
$62.66
(0%)
3-Year Target
$62.53
(-1%)
3-Yr Target (if PE normalizes)
(PE: 9→10)
$63.26
(+1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 4.0%)
$149.60
(+138%)
Base:
(SPY PE: 9.4, Growth: 4.0%)
$70.74
(+12%)
Bear:
(PE: 8.0, Growth: 4.0%)
$60.13
(-4%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 13.78 | Current EPS (TTM): $4.51
Bull Case
$101.43
(+62%)
Analyst growth 48.4%, PE expands to 15.2
Base Case
$92.21
(+47%)
Market implied 48.4%, PE stable at 13.8
Bear Case
$42.26
(-33%)
Severe decline -20.0%, PE contracts to 11.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.4 to 9.5
Stabilization Target:
$63.64
(+1.2%)
PE Expansion Potential:
+1.2%
Share BMY Analysis
Share this live BMY analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (BMY)
Bullish
3 Retail Mentions
Reddit / WSB Comments
2
Bearish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 10, 2026
Daily AI digest
AI Retail Discussion Summary:
The Actinium-225 market is projected to expand at a CAGR of 30.5% between 2026 and 2036, driven by an expanding targeted alpha therapy pipeline, increasing pharmaceutical ownership of radiopharmaceutical assets, and established nuclear medicine infrastructure.
Key Retail Themes:
Market growth drivers: expanding targeted alpha therapy pipeline, increasing pharmaceutical ownership, established nuclear medicine infrastructure
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 5:11 PM ET
Data refreshes hourly during market hours. Next update: 6:11 PM
Data refreshes hourly during market hours. Next update: 6:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BMY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Featured in Portfolios
BMY is a key holding in these high-performance investment strategies.
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ABBV
AbbVie Inc |
STRONG BUY
29 analysts |
$306 | 48 HOLD |
|
BIIB
Biogen Inc |
BUY
36 analysts |
$266 | 43 HOLD |
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1453 | 27 SELL |
|
MRK
Merck & Company Inc |
BUY
28 analysts |
$162 | 50 HOLD |
|
GILD
Gilead Sciences Inc |
STRONG BUY
28 analysts |
$175 | 37 SELL |
Advanced BMY Option Strategies
Professional options setups generated by AI based on today's BMY price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive BMY Research Pages
